Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide
- 4 December 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (9) , 1498-1507
Abstract
Bispecific antibodies (BsAbs) are currently used to treat hematologic malignancies by cross-linking cytotoxic T cells with tumor cells and thus stimulating cellular immunity. Hyperactivation of T cells leads to dysregulated cytokine release, which causes the chief toxicities of BsAbs, cytokine release syndrome (CRS) and immune effector cell–mediated neurotoxicity syndrome (ICANS). On the basis of clinical trial experiences, standard practice is to hospitalize patients for intensive monitoring during periods when the risk of CRS and ICANS is highest. A strategy to safely administer these medications outpatient would improve patient access and reduce health care–associated costs. The lessons learned from outpatient administration of chimeric antigen receptor T cell therapy (CAR-T) may be applied to BsAbs given overlapping toxicity profiles. Outpatient delivery of BsAbs is feasible but requires a specialized multidisciplinary team, a robust infrastructure with well-defined standard procedures, and significant patient support and education. Emerging clinical practices, including prophylactic anti-inflammatory therapy and modified dosing schedules, further facilitate safe outpatient administration.Keywords
This publication has 48 references indexed in Scilit:
- Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral AbstractClinical Lymphoma Myeloma and Leukemia, 2025
- Freeing Bispecifc Therapy from Inpatient Constraints: A Proposed Process for Bispecific Therapy in the Ambulatory SettingTransplantation and Cellular Therapy, 2025
- Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosingHemaSphere, 2024
- Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive reviewEuropean Journal of Cancer, 2024
- Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin LymphomaTransplantation and Cellular Therapy, 2023
- Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2022
- Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory SettingClinical Lymphoma Myeloma and Leukemia, 2022
- Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administrationeJHaem, 2021
- DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosingEBioMedicine, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019